Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions


OverviewOwnershipChartTranscripts

MYGN Stock Forecast


Myriad Genetics stock forecast is as follows: an average price target of $30.20 (represents a 126.05% upside from MYGN’s last price of $13.36) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.

MYGN Price Target


The average price target for Myriad Genetics (MYGN) is $30.20 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $21.00. This represents a potential 126.05% upside from MYGN's last price of $13.36.

MYGN Analyst Ratings


Hold

According to 13 Wall Street analysts, Myriad Genetics's rating consensus is 'Hold'. The analyst rating breakdown for MYGN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (23.08%), 10 'Hold' (76.92%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Myriad Genetics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2024Puneet SoudaLeerink Partners$21.00$15.1538.61%57.19%
Oct 14, 2024Sung Ji NamScotiabank$34.00$24.6737.82%154.49%
Sep 19, 2024Tejas SavantMorgan Stanley$32.00$28.4712.40%139.52%
Aug 27, 2024Brandon CouillardWells Fargo$35.00$27.5027.27%161.98%
Aug 07, 2024Subbu NambiGuggenheim$29.00$25.9611.71%117.07%
Jun 26, 2024Sung Ji NamScotiabank$29.00$24.6217.79%117.07%
May 13, 2024Jon PetersonPiper Sandler$28.00$25.0711.69%109.58%
Dec 21, 2023David WestenbergPiper Sandler$23.00$20.4912.25%72.16%
Oct 05, 2022Mason CarricoStephens$22.00$20.825.67%64.67%
Apr 19, 2022Goldman Sachs$23.00$23.03-0.13%72.16%

The latest Myriad Genetics stock forecast, released on Dec 09, 2024 by Puneet Souda from Leerink Partners, set a price target of $21.00, which represents a 38.61% increase from the stock price at the time of the forecast ($15.15), and a 57.19% increase from MYGN last price ($13.36).

Myriad Genetics Price Target by Period


1M3M12M
# Anlaysts138
Avg Price Target$21.00$29.00$28.88
Last Closing Price$13.36$13.36$13.36
Upside/Downside57.19%117.07%116.17%

In the current month, the average price target of Myriad Genetics stock is $21.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 57.19% increase as opposed to Myriad Genetics's last price of $13.36. This month's average price target is down -27.59% compared to last quarter, and down -27.29% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Dec 09, 2024Leerink PartnersOutperformMarket PerformDowngrade
Oct 14, 2024ScotiabankSector OutperformSector OutperformHold
Sep 19, 2024Morgan StanleyEqual-WeightInitialise
Aug 27, 2024Wells FargoOverweightInitialise
Aug 13, 2024ScotiabankOutperformOutperformHold
Aug 13, 2024Piper SandlerNeutralNeutralHold
Aug 07, 2024Cowen & Co.HoldHoldHold
Aug 07, 2024GuggenheimBuyBuyHold
Jun 26, 2024ScotiabankOutperformSector OutperformInitialise
Jun 26, 2024ScotiabankOutperformInitialise
Jun 03, 2024JefferiesUnderperformDowngrade
May 13, 2024Piper SandlerNeutralNeutralHold
May 08, 2024Leerink PartnersOutperformUpgrade
May 23, 2023SVB LeerinkMarket PerformDowngrade
May 23, 2023CitigroupNeutralDowngrade
May 23, 2023Keefe, Bruyette & WoodsMarket PerformUpgrade
May 23, 2023Goldman SachsBuyUpgrade
May 23, 2023EF HuttonHoldDowngrade
May 23, 2023Credit SuisseNeutralDowngrade
Oct 06, 2022StephensEqual-WeightInitialise

Myriad Genetics's last stock rating was published by Leerink Partners on Dec 09, 2024. The company Downgrade its MYGN rating from "Outperform" to "Market Perform".

Myriad Genetics Financial Forecast


Myriad Genetics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$191.90M-$181.20M$177.80M$156.40M$179.30M$164.90M$160.80M$167.30M$189.40M$173.10M$154.60M$145.20M$93.20M$164.00M$195.10M$186.30M
Avg Forecast$247.72M$240.12M$240.91M$232.13M$226.30M$219.55M$220.21M$212.42M$213.31M$210.76M$206.44M$193.51M$194.80M$182.32M$187.16M$171.49M$169.47M$170.07M$170.96M$156.67M$162.96M$165.04M$162.54M$154.42M$93.89M$167.38M$209.66M$202.32M$221.64M$217.77M
High Forecast$254.37M$246.56M$247.37M$238.35M$232.37M$225.44M$226.11M$220.22M$217.47M$210.85M$206.44M$193.63M$195.47M$183.87M$192.18M$176.10M$174.02M$170.07M$170.96M$156.67M$162.96M$165.04M$162.54M$154.42M$93.89M$167.38M$209.66M$202.32M$221.64M$217.77M
Low Forecast$241.95M$234.52M$235.30M$226.72M$221.03M$214.44M$215.08M$205.64M$210.12M$210.66M$206.44M$193.38M$193.36M$180.77M$182.80M$167.50M$165.53M$170.07M$170.96M$156.67M$162.96M$165.04M$162.54M$154.42M$93.89M$167.38M$209.66M$202.32M$221.64M$217.77M
# Analysts5454434810954845443435454545443
Surprise %-------------1.05%-1.06%1.05%0.92%1.05%1.05%0.99%1.01%1.17%1.12%1.65%0.87%0.44%0.81%0.88%0.86%

Myriad Genetics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $194.80M, with a low forecast of $193.36M, and a high forecast of $195.47M. MYGN's average Quarter revenue forecast represents a 1.51% increase compared to the company's last Quarter revenue of $191.90M (Sep 23).

Myriad Genetics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810954845443435454545443
EBITDA-------------$-46.10M$-297.20M$-32.70M$-31.30M$-30.30M$-4.40M$-1.80M$-29.70M$55.10M$15.10M$-28.20M$-34.70M$-23.10M$-37.60M$-110.90M$9.30M$-1.20M
Avg Forecast$-22.15M$-21.47M$-21.54M$-20.75M$-20.23M$-19.63M$-19.69M$-18.99M$-19.07M$-18.84M$-18.45M$-21.39M$-17.41M$-16.30M$-16.73M$-19.45M$-32.67M$-3.36M$-3.38M$-17.68M$-3.22M$-3.26M$-3.21M$-39.88M$-1.85M$-3.31M$-4.14M$-998.10M$-4.38M$-4.30M
High Forecast$-21.63M$-20.97M$-21.03M$-20.27M$-19.76M$-19.17M$-19.23M$-18.38M$-18.78M$-18.83M$-18.45M$-17.11M$-17.29M$-16.16M$-16.34M$-15.56M$-26.14M$-3.36M$-3.38M$-14.14M$-3.22M$-3.26M$-3.21M$-31.91M$-1.85M$-3.31M$-4.14M$-798.48M$-4.38M$-4.30M
Low Forecast$-22.74M$-22.04M$-22.11M$-21.31M$-20.77M$-20.15M$-20.21M$-19.69M$-19.44M$-18.85M$-18.45M$-25.67M$-17.47M$-16.44M$-17.18M$-23.34M$-39.20M$-3.36M$-3.38M$-21.21M$-3.22M$-3.26M$-3.21M$-47.86M$-1.85M$-3.31M$-4.14M$-1.20B$-4.38M$-4.30M
Surprise %-------------2.83%17.76%1.68%0.96%9.02%1.30%0.10%9.23%-16.91%-4.70%0.71%18.71%6.99%9.08%0.11%-2.12%0.28%

5 analysts predict MYGN's average Quarter EBITDA for Dec 21 to be $-3.22M, with a high of $-3.22M and a low of $-3.22M. This is -105.84% lower than Myriad Genetics's previous annual EBITDA (Sep 21) of $55.10M.

Myriad Genetics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810954845443435454545443
Net Income-------------$-61.30M$-116.10M$-54.70M$-42.30M$-35.10M$-14.10M$-20.50M$-7.60M$24.60M$-4.70M$-39.50M$-44.20M$-15.20M$-55.40M$-115.20M$-8.30M$-20.60M
Avg Forecast$8.95M$6.93M$7.70M$5.54M$4.88M$2.98M$1.69M$-254.97K$2.38M$1.70M$-1.06M$-35.08M$1.29M$-6.87M$-7.37M$-31.89M$-8.36M$-3.28M$2.05M$-28.99M$-1.94M$-1.46M$-8.28M$-55.86M$-38.13M$614.25K$25.08M$-1.04B$38.19M$35.51M
High Forecast$9.26M$7.18M$7.96M$5.74M$5.05M$3.08M$1.75M$1.02M$2.46M$1.74M$-1.03M$-28.07M$1.33M$-6.66M$-7.15M$-25.51M$-6.69M$-3.28M$2.05M$-23.19M$-1.94M$-1.46M$-8.28M$-44.69M$-38.13M$614.25K$25.08M$-829.44M$38.19M$35.51M
Low Forecast$8.67M$6.72M$7.46M$5.38M$4.74M$2.89M$1.64M$-1.53M$1.59M$1.67M$-1.10M$-42.10M$643.89K$-7.11M$-7.63M$-38.27M$-10.03M$-3.28M$2.05M$-34.79M$-1.94M$-1.46M$-8.28M$-67.04M$-38.13M$614.25K$25.08M$-1.24B$38.19M$35.51M
Surprise %-------------8.93%15.75%1.72%5.06%10.71%-6.89%0.71%3.91%-16.90%0.57%0.71%1.16%-24.75%-2.21%0.11%-0.22%-0.58%

Myriad Genetics's average Quarter net income forecast for Dec 21 is $-1.94M, with a range of $-1.94M to $-1.94M. MYGN's average Quarter net income forecast represents a -107.89% decrease compared to the company's last Quarter net income of $24.60M (Sep 21).

Myriad Genetics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810954845443435454545443
SG&A-------------$170.40M$140.70M$151.70M$146.50M$130.50M$127.10M$110.60M$139.30M$180.20M$134.80M$145.50M$132.90M$124.10M$107.40M$132.90M$135.60M$135.50M
Avg Forecast$195.18M$189.19M$189.81M$182.89M$178.30M$172.98M$173.50M$167.37M$168.07M$166.05M$162.65M$189.27M$153.48M$143.65M$147.46M$135.12M$85.03M$130.32M$131.00M$156.42M$124.88M$126.47M$124.56M$118.33M$71.95M$128.27M$160.67M$155.03M$169.84M$166.88M
High Forecast$200.41M$194.26M$194.90M$187.80M$183.08M$177.63M$178.15M$173.51M$171.34M$166.13M$162.65M$227.12M$154.01M$144.87M$151.41M$138.74M$102.04M$130.32M$131.00M$187.70M$124.88M$126.47M$124.56M$118.33M$71.95M$128.27M$160.67M$155.03M$169.84M$166.88M
Low Forecast$190.63M$184.78M$185.39M$178.63M$174.14M$168.95M$169.46M$162.02M$165.55M$165.98M$162.65M$151.41M$152.34M$142.43M$144.02M$131.97M$68.02M$130.32M$131.00M$125.14M$124.88M$126.47M$124.56M$118.33M$71.95M$128.27M$160.67M$155.03M$169.84M$166.88M
Surprise %-------------1.19%0.95%1.12%1.72%1.00%0.97%0.71%1.12%1.42%1.08%1.23%1.85%0.97%0.67%0.86%0.80%0.81%

Myriad Genetics's average Quarter SG&A projection for Dec 23 is $153.48M, based on 8 Wall Street analysts, with a range of $152.34M to $154.01M. The forecast indicates a -9.93% fall compared to MYGN last annual SG&A of $170.40M (Sep 23).

Myriad Genetics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810954845443435454545443
EPS-------------$-0.75$-1.42$-0.67$-0.52$-0.43$-0.18$-0.26$-0.10$0.31$-0.06$-0.52$-0.59$-0.20$-0.74$-1.55$-0.11$-0.28
Avg Forecast$0.10$0.08$0.08$0.06$0.05$0.03$0.02$-0.00$0.03$0.02$-0.01$-0.10$0.01$-0.08$-0.08$-0.19$-0.16$-0.04$0.03$-0.08$-0.02$-0.02$-0.10$-0.15$-0.47$0.01$0.31$0.31$0.47$0.43
High Forecast$0.10$0.08$0.09$0.06$0.06$0.03$0.02$0.01$0.03$0.02$-0.01$-0.10$0.01$-0.07$-0.08$-0.19$-0.16$-0.04$0.03$-0.08$-0.02$-0.02$-0.10$-0.15$-0.47$0.01$0.31$0.31$0.47$0.43
Low Forecast$0.10$0.07$0.08$0.06$0.05$0.03$0.02$-0.02$0.02$0.02$-0.01$-0.11$0.01$-0.08$-0.08$-0.20$-0.17$-0.04$0.03$-0.08$-0.02$-0.02$-0.10$-0.15$-0.47$0.01$0.31$0.31$0.47$0.43
Surprise %-------------9.93%17.51%3.47%3.18%10.75%-7.20%3.13%4.01%-17.44%0.59%3.44%1.27%-26.67%-2.42%-4.93%-0.24%-0.65%

According to 5 Wall Street analysts, Myriad Genetics's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -107.65% decrease compared to MYGN previous annual EPS of $0.31 (Sep 21).

Myriad Genetics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MYGNMyriad Genetics$13.82$30.20118.52%Hold
PSNLPersonalis$3.84$7.3892.19%Hold
ACRSAclaris Therapeutics$3.26$6.0084.05%Buy
CDNACareDx$22.14$37.5069.38%Buy
NEOGNeogen$12.13$17.5044.27%Buy
CSTLCastle Biosciences$28.14$40.5043.92%Buy
EXASExact Sciences$60.37$77.4328.26%Buy
SHCSotera Health Company$13.08$16.0022.32%Buy
RDNTRadNet$76.52$91.0018.92%Buy
GHGuardant Health$34.84$40.6016.53%Buy
QGENQiagen$45.34$48.336.59%Buy
MEDPMedpace$348.48$369.676.08%Hold
ILMNIllumina$143.12$147.783.26%Buy
TWSTTwist Bioscience$48.40$46.00-4.96%Buy
NTRANatera$168.21$151.50-9.93%Buy

MYGN Forecast FAQ


Is Myriad Genetics a good buy?

No, according to 13 Wall Street analysts, Myriad Genetics (MYGN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 23.08% of MYGN's total ratings.

What is MYGN's price target?

Myriad Genetics (MYGN) average price target is $30.2 with a range of $21 to $35, implying a 126.05% from its last price of $13.36. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Myriad Genetics stock go up soon?

According to Wall Street analysts' prediction for MYGN stock, the company can go up by 126.05% (from the last price of $13.36 to the average price target of $30.2), up by 161.98% based on the highest stock price target, and up by 57.19% based on the lowest stock price target.

Can Myriad Genetics stock reach $20?

MYGN's average twelve months analyst stock price target of $30.2 supports the claim that Myriad Genetics can reach $20 in the near future.

What is Myriad Genetics's current price target trend?

1 Wall Street analyst forecast a $21 price target for Myriad Genetics (MYGN) this month, up 57.19% from its last price of $13.36. Compared to the last 3 and 12 months, the average price target increased by 117.07% and increased by 116.17%, respectively.

What are Myriad Genetics's analysts' financial forecasts?

Myriad Genetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $878.48M (high $904.14M, low $856.18M), average EBITDA is $-78.533M (high $-76.54M, low $-80.827M), average net income is $9.3M (high $10.9M, low $7.73M), average SG&A $692.14M (high $712.36M, low $674.58M), and average EPS is $0.102 (high $0.12, low $0.0851). MYGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $960.87M (high $986.65M, low $938.49M), average EBITDA is $-85.899M (high $-83.898M, low $-88.204M), average net income is $29.12M (high $30.14M, low $28.24M), average SG&A $757.06M (high $777.37M, low $739.43M), and average EPS is $0.32 (high $0.332, low $0.311).

Did the MYGN's actual financial results beat the analysts' financial forecasts?

Based on Myriad Genetics's last annual report (Dec 2022), the company's revenue was $678.4M, beating the average analysts forecast of $667.16M by 1.68%. Apple's EBITDA was $-67.8M, beating the average prediction of $-57.083M by 18.77%. The company's net income was $-112M, beating the average estimation of $-38.581M by 190.30%. Apple's SG&A was $514.7M, beating the average forecast of $502.78M by 2.37%. Lastly, the company's EPS was $-1.39, beating the average prediction of $-0.261 by 431.87%. In terms of the last quarterly report (Sep 2023), Myriad Genetics's revenue was $191.9M, beating the average analysts' forecast of $182.32M by 5.25%. The company's EBITDA was $-46.1M, beating the average prediction of $-16.299M by 182.84%. Myriad Genetics's net income was $-61.3M, beating the average estimation of $-6.868M by 792.54%. The company's SG&A was $170.4M, beating the average forecast of $143.65M by 18.62%. Lastly, the company's EPS was $-0.75, beating the average prediction of $-0.0756 by 892.64%